Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.
نویسندگان
چکیده
Surprisingly, immunosuppressive treatment can enhance the efficacy of conventional HIV-1 antiretroviral treatment, and can be beneficial for HIV-1infected patients. This argues for a role of target cell availability in limiting the HIV-1 infection, and is in agreement with mathematical models suggesting that immunosuppression may limit the outgrowth of drugresistant escape mutants. Immunosuppressive drugs like hydroxyurea (HU) may therefore be powerful and affordable supplements to HIV-1 antiretroviral therapy.
منابع مشابه
Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
Hydroxyurea has been extensively used in medical practice, mainly for treating chronic myelogenous leukemia, sickle cell anemia, and other diseases. In light of its ability to inhibit DNA synthesis and to induce cell cycle arrest through inhibition of ribonucleotide reductase, the effects of hydroxyurea on replication of human immunodeficiency virus type 1 (HIV-1) have been investigated. In vit...
متن کاملToxic intracellular anabolite levels of tenofovir and didanosine causing a steep CD4-cell decline
Case report A 52-year-old HIV-1 positive Caucasian male started zidovudine (AZT), lamivudine, nelfinavir in 1999 at a CD4-cell count of 210/μL. In July 2007 treatment was switched because of viral blips to atazanavir, ritonavir, tenofovir, emtricitabine and didanosine (250 mg). Within one year his CD4-cell count declined from 1140 to 140/μL despite complete virological suppression [1]. Renal cl...
متن کاملHIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.
Most HIV-1 production occurs in dividing (activated) T-lymphocytes. Non-dividing resting lymphocytes and macrophages, however, might be long-term reservoirs for HIV-1. We wanted to increase the antiviral efficacy of combination therapies by targeting simultaneously reservoir cells and the virus. Hydroxyurea blocks cellular activation necessary for viral replication in CD4 T-lymphocytes, proteas...
متن کاملVS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics
BACKGROUND A new class of antiretrovirals, AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs), has been proposed as a disease-modifying therapy to both reduce Human Immunodeficiency Virus Type 1 (HIV-1) RNA levels and the excessive immune activation now recognized as the major driver of not only the continual loss of CD4(+) T cells and progression to Acquired Immunodeficiency Syndrome (...
متن کاملA Randomized Study of the Safety and Antiretroviral Activity of Hydroxyurea Combined with Didanosine in Persons Infected with Human Immunodeficiency Virus Type 1
s of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999. 17. Rutschmann O, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12:F71–F7. 18. Marschner I, Betensky R, DeGruttola V, Ha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- AIDS
دوره 12 13 شماره
صفحات -
تاریخ انتشار 1998